--- title: "DaVita Q1 2026 Margin Compression Reinforces Bearish Profitability Narratives" type: "News" locale: "en" url: "https://longbridge.com/en/news/285527428.md" description: "DaVita (DVA) reported Q1 2026 revenue of $3.4 billion and EPS of $2.93, reflecting modest growth but tighter profit margins, with net profit margins declining to 5.5% from 6.6% a year prior. Despite a trailing 12-month revenue of $13.8 billion and a growth rate of 4.7%, the company lags behind the broader market. Bulls see potential in technology and Integrated Kidney Care, while bears highlight margin compression and rising costs. The stock trades at a P/E of 16.5x, below industry averages, raising concerns about valuation amid profitability pressures." datetime: "2026-05-07T10:10:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285527428.md) - [en](https://longbridge.com/en/news/285527428.md) - [zh-HK](https://longbridge.com/zh-HK/news/285527428.md) --- # DaVita Q1 2026 Margin Compression Reinforces Bearish Profitability Narratives DaVita (DVA) opened 2026 with Q1 revenue of US$3.4b and basic EPS of US$2.93, setting the tone for how its dialysis network is converting patient volumes into earnings. Over the past five quarters, the company has seen revenue move from US$3.2b in Q1 2025 to US$3.4b in Q1 2026, while quarterly EPS has ranged from US$2.05 to US$3.18, giving a clearer view of how throughput and cost control have translated into bottom line results. With trailing 12 month net profit margins at 5.5% versus 6.6% a year earlier, this latest print lands in a context of modest growth but tighter profitability. See our full analysis for DaVita. With the latest numbers on the table, the next step is to see how this earnings profile lines up against the dominant narratives around DaVita's growth, risks, and long term profitability story. See what the community is saying about DaVita NYSE:DVA Revenue & Expenses Breakdown as at May 2026 ## TTM revenue at US$13.8b while growth lags market - On a trailing 12 month basis, DaVita booked about US$13.8b in revenue with revenue growth of 4.7% per year, compared with 11.3% per year for the broader US market. - Bulls point to technology and Integrated Kidney Care as future growth drivers. However, the current 4.7% revenue growth rate sits below both the bullish revenue assumption of about 4.8% annual growth and the wider market, which means: - The bullish view that chronic kidney disease incidence and new care programs can support steady volume growth is not strongly reflected in the recent revenue trajectory so far. - At the same time, the large existing base of US$13.8b revenue and exposure to long term dialysis demand keeps the bullish argument focused on durability of the revenue stream rather than rapid expansion. Bulls argue that Q1's earnings profile could be the starting point for margin expansion and steadier growth, and that the detailed assumptions on revenue, EPS and capital returns deserve a closer look **🐂 DaVita Bull Case** ## Margins soften as net profit slips to US$756 million - Trailing 12 month net income excluding extra items is US$756.4 million with a 5.5% net profit margin, compared with a 6.6% margin a year earlier and earnings that declined over the past five years by about 1.2% per year. - Bears focus on this margin compression and the negative recent earnings trend, arguing that higher patient care costs and IT spending could keep pressure on profitability, which lines up with: - The current 5.5% margin sitting below last year’s 6.6% level while large multi year technology and AI investments are still flowing through expenses. - Past five year earnings declining roughly 1.2% per year, which leans toward the cautious view that cost savings and clinical initiatives may take time before they improve the earnings line. Skeptics warn that a 5.5% net margin and a multi year earnings decline make the cautious case worth understanding in full **🐻 DaVita Bear Case** ## P/E of 16.5x sits between earnings pressure and mixed valuation signals - The stock trades on a trailing P/E of 16.5x, below the US Healthcare industry average of 25.2x and the US market at 19.3x, while the current share price of US$193.88 is above both the DCF fair value of about US$133.60 and the allowed analyst price target of US$167.29. - What stands out is how this lower P/E interacts with the consensus style expectations for earnings growth of roughly 7.7% per year and margin headwinds, creating a tug of war where: - The discount to the 25.2x industry P/E and to the 32x peer average supports those who see relative value despite only modest revenue growth and thinner margins. - The share price sitting above the DCF fair value of US$133.60 and above the US$167.29 analyst target highlights that some valuation frameworks flag less upside when recent margin pressure and cash flow coverage of debt are taken into account. ## Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for DaVita on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. Mixed signals on growth, margins, and valuation can be hard to balance, so move quickly from reading to reviewing the data in detail yourself, and weigh both the risks and rewards by checking the 3 key rewards and 1 important warning sign. ## See What Else Is Out There DaVita is contending with softer margins, slower revenue growth than the broader US market, and a P/E that some valuation models flag as stretched. If that mix of pressure on profitability and questions around value makes you cautious, it is worth checking the 44 high quality undervalued stocks today to compare alternatives that may better fit your return expectations. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [DVA.US](https://longbridge.com/en/quote/DVA.US.md) ## Related News & Research - [DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals | DVA Stock News](https://longbridge.com/en/news/286808813.md) - [01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation](https://longbridge.com/en/news/286359416.md) - [NephroPlus sharpens global dialysis push as overseas business grows](https://longbridge.com/en/news/287024448.md) - [Adia Med Now Recruiting for Kidney Health and Lower Back Pain Studies Listed on ClinicalTrials.gov | ADIA Stock News](https://longbridge.com/en/news/287094495.md) - [15:30 ETRegistration Launches for Emergency Nursing 2026 in Phoenix](https://longbridge.com/en/news/287109330.md)